The report highlights the extreme brutality of some BLA attacks, citing the hijacking of the Jaffar Express in Balochistan on ...

Gain insights from Ocugen's Q2 2025 earnings call, highlighting clinical advancements, strategic partnerships, BLA milestones for 2026-2027, and ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Qure advances its pathology-shifting AMT-130 therapy for Huntington's disease; pivotal data and commercial launch prep target 2025 milestones.

Balochistan Liberation Army (BLA), including its Majeed Brigade, and Tehrik-e Taliban Pakistan (TTP} — have “close coordination”, according to a United Nations Security Council report, which pointed ...

Among reasons for the rejection, the agency cited a lack of US patient representation in the STARGLO trial assessing ...

These 10 stocks could mint the next wave of millionaires › Ocugen (NASDAQ:OCGN), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its ...

uniQure (NASDAQ: QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

The United Nations Security Council report pointed out that "some BLA attacks showed a high degree of complexity and brutality", citing Jaffar Express' dramatic hijacking in Pakistan's Balochistan ...